Functional impairment in progressive supranuclear palsy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: The current study sought to describe the functional profiles of patients with early-stage progressive supranuclear palsy (PSP) in a large prospective, multisite study.
Methods: Using data from 202 individuals meeting criteria for clinically definite or probable PSP, 3 functional scales were examined. Functional scores were then compared to measures of motor, cognition, and psychiatric symptoms.
Results: Functional disability was high in early-stage PSP, with 100% of patients having less than perfect scores on all functional scales. Whereas functional scores tended not to be related to cognition or psychiatric symptoms, they were strongly related to motoric ratings.
Conclusions: Both clinically and in research settings, the definition of functional intactness/impairment has important implications. Future studies should examine if functional impairment is this high in PSP or if new scales of functional abilities need to be developed for this condition.
GLOSSARY
- ADL=
- activities of daily living;
- DRS-2=
- Dementia Rating Scale–2;
- NPI=
- Neuropsychiatric Inventory;
- PSP=
- progressive supranuclear palsy;
- PSP-RS=
- Progressive Supranuclear Palsy Rating Scale;
- SE-ADL=
- Schwab & England Activities of Daily Living Scale;
- UPDRS=
- Unified Parkinson's Disease Rating Scale
Footnotes
The Investigators and Coordinators of the ENGENE-PSP Study Group are listed on the Neurology® Web site at www.neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at www.neurology.org
- Received May 24, 2012.
- Accepted September 6, 2012.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
CoQ10 in progressive supranuclear palsyA randomized, placebo-controlled, double-blind trialDiana Apetauerova, Stephanie A. Scala, Robert W. Hamill et al.Neurology: Neuroimmunology & Neuroinflammation, August 02, 2016 -
Articles
Stereotactic ventral pallidotomy for Parkinson's diseaseM. Dogali, E. Fazzini, E. Kolodny et al.Neurology, April 01, 1995 -
Article
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scoresMaureen Leehey, Sheng Luo, Saloni Sharma et al.Neurology, September 29, 2017 -
Articles
Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's diseaseMark Guttman, International Pramipexole-Bromocriptine Study Group et al.Neurology, October 01, 1997